Autolus Therapeutics (AUTL) Common Equity (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Common Equity data on file, last reported at $178.1 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 58.32% year-over-year to $178.1 million; the trailing twelve-month figure through Dec 2025 stood at $178.1 million (down 58.32% YoY), and the FY2025 full-year result was $178.1 million, down 58.32% from the prior year.
• Common Equity for Q4 2025 stood at $178.1 million, down from $265.5 million in the prior quarter.
• Across five years, Common Equity topped out at $582.0 million in Q1 2024 and bottomed at $111.5 million in Q4 2023.
• The 5-year median for Common Equity is $271.1 million (2022), against an average of $307.2 million.
• The widest annual swing landed in 2023, when Common Equity sank 62.68%; it then surged 283.34% in 2024.
• A 5-year view of Common Equity shows it stood at $313.3 million in 2021, then slipped by 4.67% to $298.7 million in 2022, then tumbled by 62.68% to $111.5 million in 2023, then soared by 283.34% to $427.3 million in 2024, then plunged by 58.32% to $178.1 million in 2025.
• The last three Common Equity figures came in at $178.1 million (Q4 2025), $265.5 million (Q3 2025), and $346.5 million (Q2 2025), per Business Quant data.

Peer Comparison